Paper4552811
Hydroxyurea therapy in chronic myelogenous leukemia.
Kennedy BJ. Cancer, 1972. Cited by 105 papers, by iCite.
Cite this record
ConductScience Library. Hydroxyurea therapy in chronic myelogenous leukemia. Papers, record 4552811. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4552811
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hydroxyurea | Major topic |
| Leukemia, Myeloid | Major topic |
| Bone Marrow | |
| Bone Marrow Cells | |
| Busulfan | |
| Clinical Trials as Topic | |
| Drug Resistance | |
| Humans | |
| Leukocyte Count | |
| Splenomegaly | |
| Thrombocytosis |
Source PubMed
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 105 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40575311 | Oxidative and Hydrolytic HNO Formation from a Clinical Drug Hydroxyurea Catalyzed by Horseradish Peroxidase: Basic Mechanism, Active Site Effect, and Implications for Drug Design. | JACS Au | 2025 | https://conductscience.org/library/papers/40575311 | PubMed |
| 40503040 | Real-world evidence of imatinib treatment in younger and older patients with chronic myeloid leukaemia: A retrospective single centre analysis. | Oncol Lett | 2025 | https://conductscience.org/library/papers/40503040 | PubMed |
| 39157872 | Single-cell proteo-transcriptomic profiling reveals altered characteristics of stem and progenitor cells in patients receiving cytoreductive hydroxyurea in early-phase chronic myeloid leukemia. | Haematologica | 2025 | https://conductscience.org/library/papers/39157872 | PubMed |
| 36882601 | Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia. | Handb Exp Pharmacol | 2023 | https://conductscience.org/library/papers/36882601 | PubMed |
| 36092883 | Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative. | Front Genet | 2022 | https://conductscience.org/library/papers/36092883 | PubMed |
| 34262462 | Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34262462 | PubMed |
| 33435150 | Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future. | Cells | 2021 | https://conductscience.org/library/papers/33435150 | PubMed |
| 33134861 | Chronic Myeloid Leukemia in 2020. | Hemasphere | 2020 | https://conductscience.org/library/papers/33134861 | PubMed |
| 28293403 | Hydroxycarbamine: from an Old Drug Used in Malignant Hemopathies to a Current Standard in Sickle Cell Disease. | Mediterr J Hematol Infect Dis | 2017 | https://conductscience.org/library/papers/28293403 | PubMed |
| 26366626 | Hydroxyurea therapy for sickle cell anemia. | Expert Opin Drug Saf | 2015 | https://conductscience.org/library/papers/26366626 | PubMed |
| 9592619 | Pharmacokinetics and pharmacodynamics of hydroxyurea. | Clin Pharmacokinet | 1998 | https://conductscience.org/library/papers/9592619 | PubMed |
| 8452662 | Adverse haematological complications of anticancer drugs. Clinical presentation, management and avoidance. | Drug Saf | 1993 | https://conductscience.org/library/papers/8452662 | PubMed |
| 8261572 | A phase I trial of high-dose continuous-infusion hydroxyurea. | Cancer Chemother Pharmacol | 1993 | https://conductscience.org/library/papers/8261572 | PubMed |
| 3342464 | Phase 1 study of high-dose hydroxyurea in lung cancer. | Cancer Chemother Pharmacol | 1988 | https://conductscience.org/library/papers/3342464 | PubMed |
| 3277680 | Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha. | Blut | 1988 | https://conductscience.org/library/papers/3277680 | PubMed |
| 2208576 | Implications and problems in analysing cytotoxic activity of hydroxyurea in combination with a potential inhibitor of ribonucleotide reductase. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2208576 | PubMed |
| 2199009 | An overview of bone marrow transplantation for chronic myeloid leukemia. | CMAJ | 1990 | https://conductscience.org/library/papers/2199009 | PubMed |
| 1549593 | 2-Aminopurine overrides multiple cell cycle checkpoints in BHK cells. | Proc Natl Acad Sci U S A | 1992 | https://conductscience.org/library/papers/1549593 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4552811
GET https://conductscience.org/api/papers/v1/4552811/authors